@jflier @NIH No doubt. Moreover, I can assure you that the savings incurred will not be directed to increasing the pool of direct costs available for NIH grants.

Reducing the NIH indirect cost rate to 15% across-the-board will have a catastrophic impact on biomedical research. I can guarantee you that the savings incurred will not be applied to increasing the pool of direct costs supporting mor NIH grants.

@RamalingamMD Maybe we can get AI to do the peer to peer?

@DrDawnHershman @TheEmmys Very talented couple !

@RamalingamMD breaks new ground at the #ASCO24 plenary receiving 👏🏼 DURING his presentation of LAURA (and a standing ovation 👏🏼 after) showing enormous PFS benefit for adjuvant osimertinib in stage III EGFRm NSCLC.

@KarynAGoodman from @IcahnMountSinai and @TischCancer discusses clinical implications of the ESOPEC trial on the management of esophageal adenocarcinoma at the plenary session of #ASCO24, an important chapter completed, but …”not the end of the story.”

Epigenetic therapy for breast cancer -unfulfilled promise and disappointment - until now, as presented by @AACRPres today at #ASCO24 and published in @NatureMedicine.

@hoperugo @OncoAlert Insightful concluding remark that brings clarity to a complex challenge

Seeking a medical oncologist to join the Section of GU Medical Oncology led by @MattGalsky @IcahnMountSinai and @TischCancer. For more information, see:

Seeking an individual to lead the Section of Head and Neck Medical Oncology @IcahnMountSinai and @TischCancer. For more information, see:

@DrSteveMartin Thank you Balazs. You continue to bring new meaning to the word “PUNditry”.

@KalinskyKevin @hoosierdfh @WinshipAtEmory @EmoryUniversity No surprises here… many congratulations Kevin.

@FAndreMD @GustaveRoussy Congratulations! Best wishes for continued success

Time is running out to register for Best of @SABCSSanAntonio EAST on January 13th. Please join me and @Neil_Iyengar , @DrDawnHershman , @EMittendorfMD , and none other than the SABCS Program Director, Dr Kate Lathrop from @UTHealth 👇👇👇👇👇👇👇👇👇

@PTarantinoMD @DFCI_BreastOnc Indeed, when looked at another way, @RimaPatelMD found that of 3,431 post-menopausal women with 1-3 + nodes treated at Mount Sinai who would be spared chemo based on an RS 0-25, 35% were eligible for adjuvant abema based on FDA or ASCO criteria. criteria.

@LeandroJonatad1 Yes. Seems counterintuitive based on what was the standard of care for so long for up to 3+.nodes, but the current evidence would support that position in this scenario, which is not uncommon

Last chance to register for Official Best of San Antonio Breast Cancer Symposium EAST to be held in person on Saturday January 13, 2024. Look forward to seeing you there...

@jhaveri_komal @curijoey @myESMO Bravissimo!👏

@DrSteveMartin No knife or fork needed.